Actively Recruiting
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Led by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Updated on 2026-01-06
20
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
CONDITIONS
Official Title
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Up to 75 years old, any gender
- Bone marrow tests showing more than 5% primitive or immature lymphocytes, or MRD confirming B-ALL
- Positive CD19 expression confirmed by flow cytometry or histology
- Expected survival longer than 3 months as assessed by the researcher
- Eastern Cooperative Oncology Group (ECOG) score 3 or less
- Good liver, kidney, heart, and lung functions within specified limits
- Peripheral blood counts meeting minimum levels: absolute lymphocyte count ≥0.5E9/L, platelet count >30E9/L, hemoglobin >80g/L
- No active malignant cells in cerebrospinal fluid, no brain metastases or central nervous system leukemia as shown by MRI
- Agreement to use effective contraception if fertile
- Able to understand and sign informed consent
You will not qualify if you...
- Pregnant or breastfeeding women, or planning pregnancy within 6 months
- Positive for hepatitis B, hepatitis C, AIDS, syphilis, or cytomegalovirus
- History of other tumors except certain cured skin or cervical cancers
- Prior treatments targeting CD19
- Autologous stem cell transplant within 6 weeks
- Uncontrolled active bacterial or fungal infections
- Allergies to study drugs or components
- Active autoimmune diseases
- Current unstable or active ulcers or gastrointestinal bleeding
- Mental or psychological disorders preventing cooperation
- Use of other experimental drugs within last 3 months
- Grade II-IV acute graft-versus-host disease or widespread chronic GVHD
- Any other reasons deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
920th HJointLogistics
Kunming, Yunnan, China
Actively Recruiting
Research Team
S
Sanbin Wang, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here